A phase 1/2 study of NS-87/CPX-351 (cytarabine and daunorubicin liposome) in Japanese patients with high-risk acute myeloid leukemia.
Usuki K, Miyamoto T, Yamauchi T, Ando K, Ogawa Y, Onozawa M, Yamauchi T, Kiyoi H, Yokota A, Ikezoe T, Katsuoka Y, Takada S, Aotsuka N, Morita Y, Ishikawa T, Asada N, Ota S, Dohi A, Morimoto K, Imai S, Kishimoto U, Akashi K, Miyazaki Y; Study Group for NS-87/CPX-351.
Usuki K, et al. Among authors: aotsuka n.
Int J Hematol. 2024 Jun;119(6):647-659. doi: 10.1007/s12185-024-03733-z. Epub 2024 Mar 26.
Int J Hematol. 2024.
PMID: 38532078
Free PMC article.
Clinical Trial.